<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Aducanumab (Aduhelm)</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Aducanumab (Aduhelm)</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>
```mermaid
flowchart TD
%% Inputs (Blue)
A["Aducanumab<br/>mAb158"]:::blue
%% Intermediates (Orange)
B["Selectively Binds<br/>Aggregated Abeta"]:::orange
C["Soluble Oligomers<br/>Primary Target"]:::orange
D["Insoluble Plaques<br/>Amyloid Fibrils"]:::orange
%% Pathology (Red)
E["Microglial<br/>Activation"]:::red
F["Fc Receptor<br/>Engagement"]:::red
%% Outcomes (Green)
G["Enhanced<br/>Phagocytosis"]:::green
H["Plaque Clearance<br/>Amyloid PET Reduction"]:::green
I["Peripheral Sink<br/>Abeta in Blood"]:::green
J["Reduced Neuritic<br/>Plaque Burden"]:::green
K["Potential Clinical<br/>Benefit"]:::green
%% Connections
A --> B
B --> C
B --> D
C --> E
D --> E
E --> F
F --> G
G --> H
A --> I
H --> J
J --> K
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Aducanumab (Aduhelm)</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Aducanumab (Aduhelm)</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>
[^1]: Aducanumab binds to Abeta residues 3-7, exposed on aggregated but not monomeric forms [(Sevigny et al., 2016)](https://doi.org/10.1038/nature19323)
[^2]: EMERGE trial showed 71% amyloid PET reduction at 78 weeks [(Budd Haeberlein et al., 2022)](https://doi.org/10.1002/alz.12638)
Aducanumab (Aduhelm) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@sevigny2016]
Aducanumab (marketed as Aduhelm) is a human monoclonal immunoglobulin gamma 1 (IgG1) antibody that was developed by Biogen in collaboration with Neurimmune for the treatment of [alzheimers](/diseases/alzheimers-disease). On June 7, 2021, aducanumab became the first anti-[amyloid-beta](/proteins/amyloid-beta) therapy to receive approval from the United States Food and Drug Administration (FDA) under the Accelerated Approval pathway, marking a watershed moment in the field of Alzheimer's therapeutics [1](https://investors.biogen.com/news-releases/news-release-details/fda-grants-accelerated-approval-aduhelmtm-first-and-only) [2](https://www.ncbi.nlm.nih.gov/books/NBK573062/). The approval was based on the drug's demonstrated ability to reduce amyloid plaques in the brain—a surrogate biomarker reasonably likely to predict clinical benefit—rather than on definitive evidence of cognitive improvement ([Biogen et al., [2021](https://investors.biogen.com/news-releases/news-release-details/fda-grants-accelerated-approval-aduhelmtm-first-and-only)). [@fda2021]
Aducanumab selectively targets aggregated forms of [amyloid-beta](/proteins/amyloid-beta), including soluble oligomers and insoluble fibrils that constitute the amyloid plaques characteristic of Alzheimer's pathology [2](https://www.ncbi.nlm.nih.gov/books/NBK573062/). The antibody binds to a linear epitope encompassing amino acid residues 3–7 of the [amyloid-beta](/proteins/amyloid-beta) peptide, a region exposed on aggregated but not monomeric forms of the protein. This selectivity allows aducanumab to engage pathological amyloid species while largely sparing the physiological monomer [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC8491638/) ([The et al., [2016](https://doi.org/10.1038/nature19323))). [@sperling2021]
Despite its historic approval, aducanumab remained one of the most controversial drugs in the history of neurology. Biogen announced the discontinuation of aducanumab commercialization in January 2024, with the drug no longer available for purchase after November 1, 2024, as the company shifted its focus to other anti-amyloid therapies such as [lecanemab](/therapeutics/lecanemab) [4](https://www.alz.org/alzheimers-dementia/therapeutics/aducanumab). The aducanumab story offers critical lessons for drug development, regulatory science, and the application of the [amyloid-hypothesis](/mechanisms/amyloid-hypothesis) to Alzheimer's therapeutics ([Failure et al., [2021](https://doi.org/10.1002/alz.12213))). [@jack2023]
Aducanumab is a fully human IgG1 monoclonal antibody derived from a library of B cells collected from cognitively healthy elderly individuals and patients with unusually slow cognitive decline. The antibody was identified through a reverse translational medicine approach: screening for naturally occurring antibodies that might confer protection against [alzheimers](/diseases/alzheimers-disease) [2](https://www.ncbi.nlm.nih.gov/books/NBK573062/) ([Alzheimer et al., [2022](https://pubmed.ncbi.nlm.nih.gov/34807243/)). [@alzheimers2021]
The antibody binds to the N-terminal region of [amyloid-beta](/proteins/amyloid-beta) (residues 3–7), recognizing a conformational epitope that is selectively exposed on aggregated forms of the peptide. This binding profile encompasses: [@fillit2021]
Once bound to amyloid aggregates, aducanumab is thought to promote plaque clearance through Fc receptor-mediated phagocytosis by [microglia](/cell-types/microglia). This mechanism is shared with other anti-amyloid antibodies including [lecanemab](/therapeutics/lecanemab) and [donanemab](/therapeutics/donanemab), though each antibody targets different epitopes and amyloid conformations ([Centers et al., [2022](https://www.cms.gov/newsroom/press-releases/cms-finalizes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment)). [@budd2022]
Aducanumab administration produced dose- and time-dependent reductions in amyloid plaque burden as measured by amyloid PET imaging. In clinical trials, high-dose aducanumab (10 mg/kg) reduced amyloid PET signal by 59% in the ENGAGE trial, 71% in the EMERGE trial, and 61% in the Phase 1b PRIME study [1](https://investors.biogen.com/news-releases/news-release-details/fda-grants-accelerated-approval-aduhelmtm-first-and-only). [@liu2021]
The Phase 1b PRIME study (NCT01677572) was a randomized, double-blind, placebo-controlled study evaluating multiple ascending doses of aducanumab in patients with prodromal or mild [alzheimers](/diseases/alzheimers-disease) with confirmed amyloid pathology by PET imaging. The study enrolled 166 patients and demonstrated: [@sims2023]
EMERGE (NCT02484547) and ENGAGE (NCT02477800) were two identically designed, randomized, double-blind, placebo-controlled Phase 3 studies conducted across 348 sites in 20 countries [5](https://doi.org/10.1186/s13195-021-00838-z)) [6](https://doi.org/10.14283/jpad.2022.30)](https://doi.org/10.14283/jpad.2022.30))). EMERGE enrolled 1,638 patients and ENGAGE enrolled 1,647 patients aged 50–85 years with confirmed amyloid pathology who met criteria for mild cognitive impairment (MCI) due to Alzheimer's Disease or mild Alzheimer's Disease dementia. [@van2023]
Primary Endpoint (CDR-SB at 78 weeks): [@liu2022]
[aria-imaging](/entities/aria-imaging) were the most significant adverse effect observed with aducanumab treatment. ARIA encompasses two subtypes: [@cms2022]
Other commonly reported adverse effects included: [@fda2023]
In November 2020, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted nearly unanimously (10 against, 1 uncertain, 0 in favor) against approval, citing the discordant results between EMERGE and ENGAGE as insufficient evidence of clinical efficacy [3](https://pmc.ncbi.nlm.nih.gov/articles/PMC8491638/). Despite this recommendation, the FDA granted accelerated approval on June 7, 2021, basing its decision on the surrogate endpoint of amyloid plaque reduction rather than on clinical benefit. [@van2023a]
The approval triggered unprecedented controversy: [@fda2023a]
In April 2022, the Centers for Medicare & Medicaid Services (CMS) issued a national coverage determination limiting Medicare coverage of anti-amyloid antibodies to patients enrolled in qualifying clinical trials—a Coverage with Evidence Development (CED) framework that effectively restricted access to aducanumab [8](https://www.cms.gov/newsroom/press-releases/cms-finalizes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment). This decision was subsequently revised in 2023 after the traditional approval of [lecanemab](/therapeutics/lecanemab), broadening coverage for anti-amyloid antibodies with traditional FDA approval while maintaining the CED restriction for those with only accelerated approval. [@biogen2024]
Following limited commercial uptake—annual revenue never exceeded $10 million against the drug's list price of approximately $26,500 per year—Biogen announced in January 2024 that it would discontinue aducanumab and withdraw its marketing authorization. The company cited a "reprioritization" of its Alzheimer's portfolio, with resources redirected toward [lecanemab](/therapeutics/lecanemab), which had received traditional FDA approval in July 2023 based on the CLARITY AD trial [4](https://www.alz.org/alzheimers-dementia/therapeutics/aducanumab). [@nih]
Despite its commercial failure, aducanumab's development and approval had profound effects on the field: [@clarity2023]
The study of Aducanumab (Aduhelm) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@antiamyloid]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses: